Minting lottery: solo miner creates a BTC block against all odds
Raffaele Redi •
NKTR
NKTR
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration
White Paper Declaration
1BTC
Invest
20BTC
Profit
Leverage:
x20
The Power Of Leverage
Trade in the big leagues with 100 Bitcoin for every 1 Bitcoin you put in
NKTR price history
| Date | Close | Change | Change(%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 9, 2023 | 0.46 | -0.05 | -9.80% | 0.51 | 0.51 | 0.46 |
| Nov 8, 2023 | 0.50 | -0.03 | -5.66% | 0.53 | 0.54 | 0.49 |
| Nov 7, 2023 | 0.54 | 0.05 | 10.20% | 0.49 | 0.54 | 0.49 |
| Nov 6, 2023 | 0.52 | -0.02 | -3.70% | 0.54 | 0.54 | 0.51 |
| Nov 3, 2023 | 0.53 | 0.04 | 8.16% | 0.49 | 0.54 | 0.47 |
| Nov 2, 2023 | 0.48 | 0.01 | 2.13% | 0.47 | 0.49 | 0.45 |
| Nov 1, 2023 | 0.46 | 0.02 | 4.55% | 0.44 | 0.48 | 0.44 |
| Oct 31, 2023 | 0.45 | 0.02 | 4.65% | 0.43 | 0.47 | 0.43 |
| Oct 30, 2023 | 0.44 | -0.02 | -4.35% | 0.46 | 0.46 | 0.43 |
| Oct 27, 2023 | 0.46 | 0.00 | 0.00% | 0.46 | 0.48 | 0.46 |
| Oct 26, 2023 | 0.48 | 0.01 | 2.13% | 0.47 | 0.48 | 0.46 |
| Oct 25, 2023 | 0.49 | 0.01 | 2.08% | 0.48 | 0.49 | 0.44 |
| Oct 24, 2023 | 0.47 | 0.02 | 4.44% | 0.45 | 0.48 | 0.45 |
| Oct 23, 2023 | 0.46 | -0.03 | -6.12% | 0.49 | 0.49 | 0.46 |
| Oct 20, 2023 | 0.49 | -0.03 | -5.77% | 0.52 | 0.53 | 0.49 |
| Oct 19, 2023 | 0.53 | 0.01 | 1.92% | 0.52 | 0.56 | 0.50 |
| Oct 18, 2023 | 0.52 | -0.03 | -5.45% | 0.55 | 0.55 | 0.52 |
| Oct 17, 2023 | 0.55 | 0.03 | 5.77% | 0.52 | 0.56 | 0.50 |
| Oct 16, 2023 | 0.51 | 0.02 | 4.08% | 0.49 | 0.53 | 0.49 |
| Oct 13, 2023 | 0.52 | -0.01 | -1.89% | 0.53 | 0.53 | 0.51 |